Diabetic Nephropathy Market Size, Share & Industry Analysis, By Drug Class (Angiotensin Converting Enzyme (ACE) Inhibitors, Angiotensin Receptor Blockers, Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors, Mineralocorticoid Receptor Antagonists, and Others), By Distribution Channel (Hospital Pharmacies, Drug Stores & Retail Pharmacies, and Others), and Regional Forecast, 2026-2034

Last Updated: March 09, 2026 | Format: PDF | Report ID: FBI102012

We will customize the report to meet your research goals, helping you gain a competitive edge, and make informed decisions.

Schedule a 30 minutes session to understand our consulting capabilities – SCHEDULE NOW

Table of Content

Introduction
1. Market Scope
2. Market Segmentation
3. Market Methodology
4. Definitions and Assumptions
Executive Summary
Market Dynamics
1. Market Drivers
2. Market Restraints
3. Market Opportunities
4. Market Trends
Key Insights
1. Key Industry Developments – Merges, Acquisitions, and Partnerships
2. New Product Launches, By Key Players
3. Prevalence of Diabetic Nephropathy, By Key Countries
4. Pipeline Analysis (Analysis by Stage, Route of Administration, Molecule Type, Sponsor, etc.)
5. Insights on Usage of SGLT2 Inhibitors in CKD Stage 3 Patients
6. Drugs Delaying Dialysis Onset: Analysis of Ongoing Studies
7. List of Research & Educational Institutes in R&D
8. Impact of COVID 19 on the Global Diabetic Nephropathy Market
Global Diabetic Nephropathy Market Analysis, Insights and Forecast, 2021-2034
1. Market Analysis, Insights and Forecast – By Drug Class
  1. Angiotensin Converting Enzyme (ACE) Inhibitors
  2. Angiotensin Receptor Blockers
  3. Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors
  4. Mineralocorticoid Receptor Antagonists
  5. Others
2. Market Analysis, Insights and Forecast – By Distribution Channel
  1. Hospital Pharmacies
  2. Drug Stores & Retail Pharmacies
  3. Others
3. Market Analysis, Insights and Forecast – By Region
  1. North America
  2. Europe
  3. Asia Pacific
  4. Rest of the World
North America Diabetic Nephropathy Market Analysis, Insights and Forecast, 2021-2034
1. Market Analysis, Insights and Forecast – By Drug Class
  1. Angiotensin Converting Enzyme (ACE) Inhibitors
  2. Angiotensin Receptor Blockers
  3. Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors
  4. Mineralocorticoid Receptor Antagonists
  5. Others
2. Market Analysis, Insights and Forecast – By Distribution Channel
  1. Hospital Pharmacies
  2. Drug Stores & Retail Pharmacies
  3. Others
3. Market Analysis, Insights and Forecast – By Country
  1. U.S.
  2. Canada
Europe Diabetic Nephropathy Market Analysis, Insights and Forecast, 2021-2034
1. Market Analysis, Insights and Forecast – By Drug Class
  1. Angiotensin Converting Enzyme (ACE) Inhibitors
  2. Angiotensin Receptor Blockers
  3. Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors
  4. Mineralocorticoid Receptor Antagonists
  5. Others
2. Market Analysis, Insights and Forecast – By Distribution Channel
  1. Hospital Pharmacies
  2. Drug Stores & Retail Pharmacies
  3. Others
3. Market Analysis, Insights and Forecast – By Country/Sub-region
  1. U.K.
  2. Germany
  3. France
7.3.4.I taly
1. 1. Spain
  2. Scandinavia
  3. Rest of Europe
Asia Pacific Diabetic Nephropathy Market Analysis, Insights and Forecast, 2021-2034
1. Market Analysis, Insights and Forecast – By Drug Class
  1. Angiotensin Converting Enzyme (ACE) Inhibitors
  2. Angiotensin Receptor Blockers
  3. Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors
  4. Mineralocorticoid Receptor Antagonists
  5. Others
2. Market Analysis, Insights and Forecast – By Distribution Channel
  1. Hospital Pharmacies
  2. Drug Stores & Retail Pharmacies
  3. Others
3. Market Analysis, Insights and Forecast – By Country/Sub-region
  1. Japan
  2. China
  3. India
  4. Australia
  5. Southeast Asia
  6. Rest of Asia Pacific
Rest of the World Diabetic Nephropathy Market Analysis, Insights and Forecast, 2021-2034
1. Market Analysis, Insights and Forecast – By Drug Class
  1. Angiotensin Converting Enzyme (ACE) Inhibitors
  2. Angiotensin Receptor Blockers
  3. Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors
  4. Mineralocorticoid Receptor Antagonists
  5. Others
2. Market Analysis, Insights and Forecast – By Distribution Channel
  1. Hospital Pharmacies
  2. Drug Stores & Retail Pharmacies
  3. Others
Comparative Analysis
1. Global Market Share Analysis (2025)
2. Company Profiles
  1. Janssen Pharmaceuticals, Inc.
    1. Overview
    2. Products & Services
    3. SWOT Analysis
    4. Recent Developments
    5. Strategies
    6. Financials (Based on Availability)
  2. AstraZeneca
    1. Overview
    2. Products & Services
    3. SWOT Analysis
    4. Recent Developments
    5. Strategies
    6. Financials (Based on Availability)
  3. Aurobindo Pharmaceuticals
    1. Overview
    2. Products & Services
    3. SWOT Analysis
    4. Recent Developments
    5. Strategies
    6. Financials (Based on Availability)
  4. Novartis AG
    1. Overview
    2. Products & Services
    3. SWOT Analysis
    4. Recent Developments
    5. Strategies
    6. Financials (Based on Availability)
  5. Sanofi
    1. Overview
    2. Products & Services
    3. SWOT Analysis
    4. Recent Developments
    5. Strategies
    6. Financials (Based on Availability)
  6. Bayer AG
    1. Overview
    2. Products & Services
    3. SWOT Analysis
    4. Recent Developments
    5. Strategies
    6. Financials (Based on Availability)
  7. Par Pharmaceutical
    1. Overview
    2. Products & Services
    3. SWOT Analysis
    4. Recent Developments
    5. Strategies
    6. Financials (Based on Availability)
  8. Sun Pharmaceutical Industries
    1. Overview
    2. Products & Services
    3. SWOT Analysis
    4. Recent Developments
    5. Strategies
    6. Financials (Based on Availability)
  9. Teva Pharmaceutical Industries Ltd.
    1. Overview
    2. Products & Services
    3. SWOT Analysis
    4. Recent Developments
    5. Strategies
    6. Financials (Based on Availability)

Introduction
1. Market Scope
2. Market Segmentation
3. Market Methodology
4. Definitions and Assumptions
Executive Summary
Market Dynamics
1. Market Drivers
2. Market Restraints
3. Market Opportunities
4. Market Trends
Key Insights
1. Key Industry Developments – Merges, Acquisitions, and Partnerships
2. New Product Launches, By Key Players
3. Prevalence of Diabetic Nephropathy, By Key Countries
4. Pipeline Analysis (Analysis by Stage, Route of Administration, Molecule Type, Sponsor, etc.)
5. Insights on Usage of SGLT2 Inhibitors in CKD Stage 3 Patients
6. Drugs Delaying Dialysis Onset: Analysis of Ongoing Studies
7. List of Research & Educational Institutes in R&D
8. Impact of COVID 19 on the Global Diabetic Nephropathy Market
Global Diabetic Nephropathy Market Analysis, Insights and Forecast, 2021-2034
1. Market Analysis, Insights and Forecast – By Drug Class
  1. Angiotensin Converting Enzyme (ACE) Inhibitors
  2. Angiotensin Receptor Blockers
  3. Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors
  4. Mineralocorticoid Receptor Antagonists
  5. Others
2. Market Analysis, Insights and Forecast – By Distribution Channel
  1. Hospital Pharmacies
  2. Drug Stores & Retail Pharmacies
  3. Others
3. Market Analysis, Insights and Forecast – By Region
  1. North America
  2. Europe
  3. Asia Pacific
  4. Rest of the World
North America Diabetic Nephropathy Market Analysis, Insights and Forecast, 2021-2034
1. Market Analysis, Insights and Forecast – By Drug Class
  1. Angiotensin Converting Enzyme (ACE) Inhibitors
  2. Angiotensin Receptor Blockers
  3. Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors
  4. Mineralocorticoid Receptor Antagonists
  5. Others
2. Market Analysis, Insights and Forecast – By Distribution Channel
  1. Hospital Pharmacies
  2. Drug Stores & Retail Pharmacies
  3. Others
3. Market Analysis, Insights and Forecast – By Country
  1. U.S.
  2. Canada
Europe Diabetic Nephropathy Market Analysis, Insights and Forecast, 2021-2034
1. Market Analysis, Insights and Forecast – By Drug Class
  1. Angiotensin Converting Enzyme (ACE) Inhibitors
  2. Angiotensin Receptor Blockers
  3. Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors
  4. Mineralocorticoid Receptor Antagonists
  5. Others
2. Market Analysis, Insights and Forecast – By Distribution Channel
  1. Hospital Pharmacies
  2. Drug Stores & Retail Pharmacies
  3. Others
3. Market Analysis, Insights and Forecast – By Country/Sub-region
  1. U.K.
  2. Germany
  3. France
7.3.4.I taly
1. 1. Spain
  2. Scandinavia
  3. Rest of Europe
Asia Pacific Diabetic Nephropathy Market Analysis, Insights and Forecast, 2021-2034
1. Market Analysis, Insights and Forecast – By Drug Class
  1. Angiotensin Converting Enzyme (ACE) Inhibitors
  2. Angiotensin Receptor Blockers
  3. Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors
  4. Mineralocorticoid Receptor Antagonists
  5. Others
2. Market Analysis, Insights and Forecast – By Distribution Channel
  1. Hospital Pharmacies
  2. Drug Stores & Retail Pharmacies
  3. Others
3. Market Analysis, Insights and Forecast – By Country/Sub-region
  1. Japan
  2. China
  3. India
  4. Australia
  5. Southeast Asia
  6. Rest of Asia Pacific
Rest of the World Diabetic Nephropathy Market Analysis, Insights and Forecast, 2021-2034
1. Market Analysis, Insights and Forecast – By Drug Class
  1. Angiotensin Converting Enzyme (ACE) Inhibitors
  2. Angiotensin Receptor Blockers
  3. Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors
  4. Mineralocorticoid Receptor Antagonists
  5. Others
2. Market Analysis, Insights and Forecast – By Distribution Channel
  1. Hospital Pharmacies
  2. Drug Stores & Retail Pharmacies
  3. Others
Comparative Analysis
1. Global Market Share Analysis (2025)
2. Company Profiles
  1. Janssen Pharmaceuticals, Inc.
    1. Overview
    2. Products & Services
    3. SWOT Analysis
    4. Recent Developments
    5. Strategies
    6. Financials (Based on Availability)
  2. AstraZeneca
    1. Overview
    2. Products & Services
    3. SWOT Analysis
    4. Recent Developments
    5. Strategies
    6. Financials (Based on Availability)
  3. Aurobindo Pharmaceuticals
    1. Overview
    2. Products & Services
    3. SWOT Analysis
    4. Recent Developments
    5. Strategies
    6. Financials (Based on Availability)
  4. Novartis AG
    1. Overview
    2. Products & Services
    3. SWOT Analysis
    4. Recent Developments
    5. Strategies
    6. Financials (Based on Availability)
  5. Sanofi
    1. Overview
    2. Products & Services
    3. SWOT Analysis
    4. Recent Developments
    5. Strategies
    6. Financials (Based on Availability)
  6. Bayer AG
    1. Overview
    2. Products & Services
    3. SWOT Analysis
    4. Recent Developments
    5. Strategies
    6. Financials (Based on Availability)
  7. Par Pharmaceutical
    1. Overview
    2. Products & Services
    3. SWOT Analysis
    4. Recent Developments
    5. Strategies
    6. Financials (Based on Availability)
  8. Sun Pharmaceutical Industries
    1. Overview
    2. Products & Services
    3. SWOT Analysis
    4. Recent Developments
    5. Strategies
    6. Financials (Based on Availability)
  9. Teva Pharmaceutical Industries Ltd.
    1. Overview
    2. Products & Services
    3. SWOT Analysis
    4. Recent Developments
    5. Strategies
    6. Financials (Based on Availability)

Read Less

List of Figures

Figure 01: Global Diabetic Nephropathy Market Revenue Breakdown (USD billion, %) by Region, 2025 & 2034

Figure 02: Global Diabetic Nephropathy Market Revenue Share (%), By Drug Class, 2025 & 2034

Figure 03: Global Diabetic Nephropathy Market Revenue Share (%), By Distribution Channel, 2025 & 2034

Figure 04: Global Diabetic Nephropathy Market Value (USD billion), by Region, 2025 & 2034

Figure 05: North America Diabetic Nephropathy Market Value (USD billion), by Drug Class, 2025 & 2034

Figure 06: North America Diabetic Nephropathy Market Value Share (%), by Drug Class, 2025

Figure 07: North America Diabetic Nephropathy Market Value (USD billion), by Distribution Channel, 2025 & 2034

Figure 08: North America Diabetic Nephropathy Market Value Share (%), by Distribution Channel, 2025

Figure 09: North America Diabetic Nephropathy Market Value (USD billion), by Country, 2025 & 2034

Figure 10: North America Diabetic Nephropathy Market Value Share (%), by Country, 2025

Figure 11: Europe Diabetic Nephropathy Market Value (USD billion), by Drug Class, 2025 & 2034

Figure 12: Europe Diabetic Nephropathy Market Value Share (%), by Drug Class, 2025

Figure 13: Europe Diabetic Nephropathy Market Value (USD billion), by Distribution Channel, 2025 & 2034

Figure 14: Europe Diabetic Nephropathy Market Value Share (%), by Distribution Channel, 2025

Figure 15: Europe Diabetic Nephropathy Market Value (USD billion), by Country/Sub-Region, 2025 & 2034

Figure 16: Europe Diabetic Nephropathy Market Value Share (%), by Country/Sub-Region, 2025

Figure 17: Asia Pacific Diabetic Nephropathy Market Value (USD billion), by Drug Class, 2025 & 2034

Figure 18: Asia Pacific Diabetic Nephropathy Market Value Share (%), by Drug Class, 2025

Figure 19: Asia Pacific Diabetic Nephropathy Market Value (USD billion), by Distribution Channel, 2025 & 2034

Figure 20: Asia Pacific Diabetic Nephropathy Market Value Share (%), by Distribution Channel, 2025

Figure 21: Asia Pacific Diabetic Nephropathy Market Value (USD billion), by Country/Sub-Region, 2025 & 2034

Figure 22: Asia Pacific Diabetic Nephropathy Market Value Share (%), by Country/Sub-Region, 2025

Figure 23: Rest of the World Diabetic Nephropathy Market Value (USD billion), by Drug Class, 2025 & 2034

Figure 24: Rest of the World Diabetic Nephropathy Market Value Share (%), by Drug Class, 2025

Figure 25: Rest of the World Diabetic Nephropathy Market Value (USD billion), by Distribution Channel, 2025 & 2034

Figure 26: Rest of the World Diabetic Nephropathy Market Value Share (%), by Distribution Channel, 2025

Figure 27: Global Diabetic Nephropathy Market Share (%), By Company, 2025

List of Tables

Table 01: Global Diabetic Nephropathy Market Revenue (USD billion) Forecast, By Drug Class, 2021-2034

Table 02: Global Diabetic Nephropathy Market Revenue (USD billion) Forecast, By Distribution Channel, 2021-2034

Table 03: Global Diabetic Nephropathy Market Revenue (USD billion) Forecast, By Region, 2021-2034

Table 04: North America Diabetic Nephropathy Market Revenue (USD billion) Forecast, by Drug Class, 2021–2034

Table 05: North America Diabetic Nephropathy Market Revenue (USD billion) Forecast, by Distribution Channel, 2021–2034

Table 06: North America Diabetic Nephropathy Market Revenue (USD billion) Forecast, by Country, 2021–2034

Table 07: Europe Diabetic Nephropathy Market Revenue (USD billion) Forecast, by Drug Class, 2021–2034

Table 08: Europe Diabetic Nephropathy Market Revenue (USD billion) Forecast, by Distribution Channel, 2021–2034

Table 09: Europe Diabetic Nephropathy Market Revenue (USD billion) Forecast, by Country/Sub-Region, 2021-2034

Table 10: Asia Pacific Diabetic Nephropathy Market Revenue (USD billion) Forecast, by Drug Class, 2021–2034

Table 11: Asia Pacific Diabetic Nephropathy Market Revenue (USD billion) Forecast, by Distribution Channel, 2021–2034

Table 12: Asia Pacific Diabetic Nephropathy Market Revenue (USD billion) Forecast, by Country/Sub-Region, 2021-2034

Table 13: Rest of the World Diabetic Nephropathy Market Revenue (USD billion) Forecast, by Drug Class, 2021–2034

Table 14: Rest of the World Diabetic Nephropathy Market Revenue (USD billion) Forecast, by Distribution Channel, 2021–2034

STUDY PERIOD: 2021-2034
BASE YEAR: 2025
HISTORICAL DATA: 2021-2024
NO OF PAGES: 120

Buy Now

Download Free Sample

Security Code

Get 20% Free Customization

Expand Regional and Country Coverage, Segments Analysis, Company Profiles, Competitive Benchmarking, and End-user Insights.

Growth Advisory Services

Clients

Related Reports

Diabetic Neuropathy Market

Get In Touch With Us

US +1 833 909 2966 ( Toll Free )

UK +44 808 502 0280 ( Toll Free )

(APAC) +91 744 740 1245
sales@fortunebusinessinsights.com